The effect of aerobic training on serum levels of Galectin3 and inflammatory markers in elderly women with metabolic syndrome: a randomized clinical trial

Document Type : Original Article


Assistant Professor of Exercise Physiology, Islamic Azad University, Hashtgerd Branch, Alborz, Iran


Introduction. Galectin3 has been recognized as a new biomarker for cardiovascular disorders, However the effects of aerobic training on theses markers have not been identified. Therefore, the purpose of the present study was to investigate the effect of aerobic training on serum levels of Galectin3 and inflammatory markers in elderly women with metabolic syndrome.
Subjects and Methods: 24 elderly women with metabolic syndrome (age: 65.37±4.08, weight: 88.98±6.56, BMI: 34.14±1.47) were randomly divided into two groups of aerobic training (n=12) and control group (n=12). The aerobic training protocol was administered for 12 weeks, three sessions per week with intensity of 65-50% of maximum heart rate. Serum samples were collected in pre-test and post-test for ELISA using Galectin3, TNF-α and CRP.
Results. Aerobic training resulted in a significant decrease in serum Galectin3 compared to control group (P˂0.05). Also, aerobic training was associated with a significant decrease in inflammatory markers (CRP and TNF-α) (P˂0.05).
Conclusion. The findings of the present study showed that aerobic training is associated with a decrease in serum Galectin3 in elderly women with metabolic syndrome, which may be due to the improvement of chronic inflammation.
Key word: Aerobic Training, Galectin 3, Inflammatory Markers, Metabolic Syndrome, Aging


1-Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. Jama. 2015;313(19):1973-4.
2-Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. Jama. 2014;311(8):806-14.
3-Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation research. 2005;96(9):939-49.
4-Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. The Journal of clinical investigation. 2017;127(1):1-4.
5-Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annual review of immunology. 2011;29:415-45.
6-Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Molecular and cellular endocrinology. 2010;316(2):129-39.
7-Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor‐Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. Journal of cellular biochemistry. 2018;119(1):105-10.
8-Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arteriosclerosis, thrombosis, and vascular biology. 2004;24(5):816-23.
9-Costa L, Canani L, Lisboa H, Tres G, Gross J. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabetic Medicine. 2004;21(3):252-5.
10-Libby P. Inflammation in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2012;32(9):2045-51.
11-Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? : Elsevier; 2004.
12-Chen K, Jiang R, Wang C, Yin Z, Fan Y, Cao J, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013;17(8):1005-11.
13-Cheng JM, Akkerhuis KM, Battes LC, Vark LC, Hillege HL, Paulus WJ, et al. Biomarkers of heart failure with normal ejection fraction: a systematic review. European journal of heart failure. 2013;15(12):1350-62.
14-Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arteriosclerosis, thrombosis, and vascular biology. 2008;28(3):433-40.
15-Sriram DK, Gowri G, Haridoss S, Venkatesan S, Rajendran I, George M. Association of galectin-3 with high cardiovascular risk in patients with type 2 diabetes attending a multi-specialty hospital in South India. International Journal of Research in Medical Sciences. 2016;4(12):5417-21.
16-Vora A, de Lemos JA, Ayers C, Grodin JL, Lingvay I. Association of Galectin-3 with Diabetes Mellitus in the Dallas Heart Study. The Journal of Clinical Endocrinology & Metabolism. 2019.
17-Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes care. 2010;33(12):e147-e67.
18-Association AD. Standards of medical care in diabetes—2014. Diabetes care. 2014;37(Supplement 1):S14-S80.
19-Chodzko-Zajko WJ, Proctor DN, Singh MAF, Minson CT, Nigg CR, Salem GJ, et al. Exercise and physical activity for older adults. Medicine & science in sports & exercise. 2009;41(7):1510-30.
20-Stefanyk LE, Dyck DJ. The interaction between adipokines, diet and exercise on muscle insulin sensitivity. Current Opinion in Clinical Nutrition & Metabolic Care. 2010;13(3):255-9.
21-El-Kader SMA, Al-Jiffri OH, Al-Shreef FM. Aerobic exercises alleviate symptoms of fatigue related to inflammatory cytokines in obese patients with type 2 diabetes. African health sciences. 2015 15(4);1142-8.
22-El-Kader SA, Gari A, El-Den AS. Impact of moderate versus mild aerobic exercise training on inflammatory cytokines in obese type 2 diabetic patients: a randomized clinical trial. African health sciences. 2013;13(4):857-63.
23-Salvagno GL, Schena F, Gelati M, Danese E, Cervellin G, Guidi GC, et al. The concentration of high-sensitivity troponin I, galectin-3 and NT-proBNP substantially increase after a 60-km ultramarathon. Clinical Chemistry and Laboratory Medicine (CCLM). 2014;52(2):26.72-7.
24-Khajeian N, Moghadasi M. Effect of 8 weeks regular endurance training on galectin-3 changes after a strenuous aerobic exercise. Journal of Physical Activity and Hormones. 2013;1 (3): 029-038
25-Farinha JB, Steckling FM, Stefanello ST, Cardoso MS, Nunes LS, Barcelos RP, et al. Response of oxidative stress and inflammatory biomarkers to a 12-week aerobic exercise training in women with metabolic syndrome. Sports medicine - open. 2015;1(1):19.
26-Saghebjoo M, Nezamdoost Z, Ahmadabadi F, Saffari I, Hamidi A. The effect of 12 weeks of aerobic training on serum levels high sensitivity C-reactive protein, tumor necrosis factor-alpha, lipid profile and anthropometric characteristics in middle-age women patients with type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2018;12(2):163-8.
27-Oberbach A, Lehmann S, Kirsch K, Krist J, Sonnabend M, Linke A, et al. Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the− 174G/C variant in IL-6 gene. European Journal of Endocrinology. 2008;159(2):129-36.
28-Jorge MLMP, de Oliveira VN, Resende NM, Paraiso LF, Calixto A, Diniz ALD, et al. The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus. Metabolism. 2011;60(9):1244-52.
29-Kim KB. Effect of different training mode on Interleukin-6 (IL-6) and C-reactive protein (CRP) in type 2 diabetes mellitus (T2DM) patients. Journal of exercise nutrition & biochemistry. 2014;18(4):371.
30-Bijeh N, Hosseini SA, Hejazi K. The effect of aerobic exercise on serum C - reactive protein and leptin levels in untrained middle-aged women. Iranian journal of public health. 2012;41(9):36-41.
31-Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. Clinica chimica acta. 2010;411(11-12):785-93.
32-Ventre J, Doebber T, Wu M, MacNaul K, Stevens K, Pasparakis M, et al. Targeted disruption of the tumor necrosis factor-α gene: metabolic consequences in obese and nonobese mice. Diabetes. 1997;46(9):1526-31.
33-Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing research reviews. 2011;10(3):319-29.
34-Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875.
35-Casas J, Shah T, Hingorani A, Danesh J, Pepys M. C‐reactive protein and coronary heart disease: a critical review. Journal of internal medicine. 2008;264(4):295-314.
36-Schindler R, Mancilla J, Endres S, Ghorbani R, Clark S, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75(1):40-7.
37-Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunologic research. 2001;24(2):163-76.
38-Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New England journal of medicine. 1999;340(6):44-54-8.
39-Issa S, Christensen A, Lottenburger T, Junker K, Lindegaard H, Hørslev‐Petersen K, et al. Within‐day variation and influence of physical exercise on circulating Galectin‐3 in patients with rheumatoid arthritis and healthy individuals. Scandinavian journal of immunology. 2015;82(1):70-5.
40-Le Goff C, Kaux J-F, Segura JF, Stojkovic V, Ancion A, Seidel L, et al. Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group. Clinical Chemistry and Laboratory Medicine (CCLM). 2019.
41-Ghassami M, Naraghi S. Galectin-3 concentrations in response to an exhaustive aerobic exercise. Journal of Physical Activity and Hormones. 2019;2(4):39-50.
42-Billebeau G, Vodovar N, Sadoune M, Launay JM, Beauvais F, Cohen-Solal A. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. European journal of preventive cardiology. 2017;24(11):1127-35.
43-Fernandes-Silva MM, Guimaraes GV, Rigaud VO, Lofrano-Alves MS, Castro RE, de Barros Cruz LG, et al. Inflammatory biomarkers and effect of exercise on functional capacity in patients with heart failure: Insights from a randomized clinical trial. European journal of preventive cardiology. 2017;24(8):808-17.
44-Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochimica et Biophysica Acta (BBA)-General Subjects. 2006;1760(4):616-35.
45-Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF, et al. Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacology and immunotoxicology. 2010;32(1):160-4.
46-Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One. 2013;8(2):e57915.
47-Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, et al. Galectin-3 deficiency accelerates high-fat diet–induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 2013;62(6):1932-44.
48-Nayor M, Wang N, Larson MG, Vasan RS, Levy D, Ho JE. Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community. Journal of the American Heart Association. 2015;5(1):e002347.